Tracking Inflammatory Cells Using Superparamagnetic Particles of Iron Oxide (SPIO) and Magnetic Resonance Imaging (MRI)
In Vivo Tracking of Magnetically-labelled Human Mononuclear Cells Using MRI Scanning
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Scotland
-
Edinburgh, Scotland, United Kingdom, EH16SU4
- University of Edinburgh / Royal Infirmary of Edinburgh
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male or female volunteers age 18 to 65 years
- Previous vaccine for tuberculosis more than 5 years ago
Exclusion Criteria:
- pregnancy / breast feeding
- Contra-indication to MRI scanning
- Inability or refusal to give informed consent
- Renal failure (eGFR <25mL/min) or hepatic dysfunction (Child's B or C)
- HIV/hepatitis B/hepatitis C/HTLV/syphilis
- Active malignant disease
- Anaemia
- Blood dyscrasia
- High risk of allergy to protamine sulphate (fish allergy, infertile men, vasectomy)
- Known history of tuberculosis infection.
- History of prolonged residence (> 6 months) in a region or country with a high prevalence of tuberculosis.
- Previous Mantoux reaction of 15mm of greater.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Administration of Intra-dermal SPIO
MRI scanning before and after intra-dermal injection of SPIO.
|
single dose, intradermal
|
|
Experimental: Mantoux, Venesection, Labelled cells
Mantoux test then MRI scanning before and after administration of iron-labelled cells obtained by venesection.
|
single dose, intradermal
single dose, intravenous
|
|
Experimental: Mantoux, Apheresis, Labelled cells
Mantoux test then MRI scanning before and after administration of iron-labelled cells obtained by apheresis.
|
single dose, intradermal
single dose, intravenous
|
|
Experimental: Mantoux, Administration of Endorem
Mantoux test then MRI scanning before and after administration of Endorem.
|
single dose, intradermal
single dose, intravenous
|
|
Experimental: Mantoux only
Mantoux test then serial MRI scanning.
|
single dose, intradermal
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in signal intensity in the region of interest on MRI scanning
Time Frame: 0 hours, 24 hours, 48 hours, 3 - 5 days
|
0 hours, 24 hours, 48 hours, 3 - 5 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jenny M Richards, MBChB MRCS, University of Edinburgh
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 10/S1102/31
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.